Strides Pharma Shares Soar 12% on Strong Q3 Results, Positive Outlook

• Strides Pharma's shares jumped 12% after announcing robust December quarter results.
• Net profit surged to ₹202 crore from ₹88 crore year-on-year, with revenue reaching ₹1,194.6 crore.
• EBITDA increased by 12.2% to ₹235.8 crore, and margin improved by 150 basis points to 19.7%.
• US sales were $70 million, and the company reiterated its $400 million US revenue outlook by FY28.
• Growth Markets revenue rose 19% to $16.6 million, driven by the Africa business.

Why It Matters: Strides Pharma's strong Q3 performance and positive business outlook led to a significant 12% share price increase.